Biotech News
Related news
ROIVRoivant2026-05-20 11:00 EST
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
ROIVRoivant2026-07-23 20:05 EST
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Roivant
Vant Operating Model Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities. Brepocitinib Autoimmune Franchise Brepocitinib is an oral JAK1/TYK2...
Recent company news
ROIVRoivant2026-08-06 11:00 EST
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
ROIVRoivant2026-08-06 11:00 EST
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
ROIVRoivant2026-07-23 20:05 EST
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
ROIVRoivant2026-05-20 11:00 EST
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
ROIVRoivant2026-05-11 20:05 EST
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
Stock data
- Close
- 36.30 USD
- Market cap
- 20.32B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States